Skandinaviska Enskilda Banken Ab (Publ) Krystal Biotech, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $21.6 Billion
- Q4 2024
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 89,047 shares of KRYS stock, worth $13.5 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
89,047
Previous 126,082
29.37%
Holding current value
$13.5 Million
Previous $22.9 Million
39.16%
% of portfolio
0.06%
Previous 0.11%
Shares
14 transactions
Others Institutions Holding KRYS
# of Institutions
311Shares Held
24.6MCall Options Held
503KPut Options Held
384K-
Black Rock Inc. New York, NY3.95MShares$597 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.88MShares$436 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.62MShares$397 Million7.18% of portfolio
-
State Street Corp Boston, MA1.45MShares$220 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$150 Million9.67% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $3.88B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...